Shares of CureVac N.V. (CVAC) tumbled 5.03% in pre-market trading on Thursday following the release of the company's fourth quarter and full-year 2024 financial results. The German biopharmaceutical firm, known for its mRNA technology, reported wider losses and a decline in revenue for the fourth quarter, disappointing investors.
CureVac announced a pre-tax loss of €38.6 million for the three months ended December 31, 2024, compared to a loss of €86.5 million in the same period of 2023. While the loss narrowed year-over-year, it was accompanied by a significant drop in revenue. The company reported Q4 2024 revenue of €14.5 million, down from €22.6 million in the previous year, representing a decrease of €8.1 million.
Despite the challenging quarter, CureVac highlighted some positive aspects in its report. The company's cash and cash equivalents position improved to €481.7 million at the end of December 2024, up from €402.5 million at the end of 2023. However, this increase was largely attributed to extraordinary payments, including a €400 million upfront payment from a new licensing agreement with GSK. CureVac reaffirmed its expected cash runway into 2028, which may provide some reassurance to long-term investors. Nevertheless, the market's immediate reaction suggests concerns about the company's current financial performance and near-term prospects.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.